Increased Investment in the Biomarker Business
First written in FY2017. 16 of 25 entries say "Restated". Latest entry: FY2024-Q2.
1 other company's latest entry also says "Restated".
- FY2024-Q2RestatedAnnual report
「In research and development, we worked on additional development of comprehensive support services for functional-materials development and promoted the joint development of mental-health biomarkers.」
The company continues additional development of comprehensive support services for functional-materials development and joint development of mental-health biomarkers. - FY2024-Q1RestatedAnnual report
「In this business segment, we worked to increase orders for and pursue additional development of comprehensive support services for functional-materials development, while promoting business alliances for new services and the joint development of mental-health biomarkers.」
The company continues the joint development of mental-health biomarkers. - FY2023-Q3RestatedAnnual report
「In this business segment, we advanced the joint development of the depression biomarker and expanded sales of the skin-gas measurement service and exosome purification columns. We also promoted research and development of new businesses for healthcare-related companies, resulting in higher research and development expenses.」
The company continues the joint development of the depression biomarker, expanded sales of the skin-gas measurement service and exosome purification columns, and research and development of new businesses. - FY2023-Q2AdvancedAnnual report
「In this business segment, we advanced the joint development of the depression biomarker and expanded sales of the skin-gas measurement service. As one result of joint research related to exosomes, we launched a new exosome purification column product in December 2022. We also promoted research and development of new businesses for healthcare-related companies.」
The company advanced the joint development of the depression biomarker, expanded sales of the skin-gas measurement service, launched a new product resulting from joint research related to exosomes, and pursued research and development of new businesses for healthcare-related companies. - FY2023-Q1AdvancedAnnual report
「In this business segment, we advanced the joint development of the depression biomarker and expanded sales of the skin-gas measurement service, which began being offered in May 2022. We also promoted joint research related to exosomes and research and development of new businesses for healthcare-related companies.」
In addition to joint development of the depression biomarker, the company specifically advanced joint research related to exosomes and research and development of new businesses for healthcare-related companies. - FY2022-Q3RestatedAnnual report
「In the healthcare solutions business (formerly the biomarker business), we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
The company continues research and development toward commercializing the depression biomarker and consideration of new pipelines and related businesses. - FY2022-Q2AdvancedAnnual report
「In the healthcare solutions business, formerly the biomarker business, we continued research and development toward commercializing the biomarker for major depressive disorder (hereinafter, the “depression biomarker”) and considered new pipelines and related businesses, while launching a new service for biomarker discovery.」
The company continued research and development of the depression biomarker and consideration of new pipelines and related businesses, advancing to the launch stage for its biomarker discovery service. - FY2022-Q1AdvancedAnnual report
「We also continued working on development toward the launch of a biomarker discovery service and on promoting joint development for healthcare solutions and services.」
In addition to research and development centered on the existing depression biomarker, the company specifically described development toward launching a biomarker discovery service and joint development of healthcare solutions and services. - FY2021RaisedAnnual report
「In this business segment, we efficiently continued joint research on PEA (the depression biomarker), development of measurement methods, and joint research on a mild cognitive impairment biomarker. We also continued working on new business development.」
In addition to the existing depression biomarker, the company explicitly identified joint research on a mild cognitive impairment biomarker and new business development, broadening its scope. - FY2021-Q3RestatedAnnual report
「In this business segment, we efficiently continued the joint development of PEA (the depression biomarker), development of measurement methods, and expansion of commissioned research-use testing. We also continued working on business development and research for new pipelines and biomarker-related businesses.」
The company continues the joint development of PEA, development of measurement methods, expansion of commissioned research-use testing, and business development for new pipelines and related businesses. - FY2021-Q2RestatedAnnual report
「In this business segment, we continued the joint development of PEA (the depression biomarker), development of measurement methods, and expansion of commissioned research-use testing. We also continued working on business development and research for new pipelines and biomarker-related businesses.」
In addition to the joint development of PEA, development of measurement methods, and expansion of commissioned research-use testing, the company continues business development and research for new pipelines and related businesses. - FY2021-Q1RestatedAnnual report
「In this business segment, we continued expanding commissioned research-use testing for PEA (the depression biomarker) and developing measurement methods. We also continued working on business development and research for new pipelines and biomarker-related businesses.」
The company continues commissioned research-use testing for PEA, development of measurement methods, and business development and research for new pipelines and related businesses. - FY2020RestatedAnnual report
「We also worked on business development and research and development for new pipelines and biomarker-related businesses.」
The company continues business development and research and development for new pipelines and biomarker-related businesses. - FY2020-Q3RestatedAnnual report
「In the biomarker business, we continued research and development toward commercializing the biomarker for major depressive disorder (hereinafter, the “depression biomarker”), while also considering new pipelines and related businesses. We also worked on business development and research for new pipelines and biomarker-related businesses and on strengthening research facilities.」
In addition to research and development of the depression biomarker, the company continues business development for new pipelines and related businesses and the strengthening of research facilities. - FY2020-Q2RestatedAnnual report
「We also worked on business development for new pipelines and biomarker-related businesses and on strengthening research facilities.」
In addition to business development for new pipelines and related businesses, the company continues to strengthen research facilities. - FY2020-Q1RestatedAnnual report
「In this business segment, we continued developing measurement methods and activities toward clinical research, including clinical performance evaluations, with a view to the practical application and commercialization of the depression biomarker. We also worked on business development for new pipelines and biomarker-related businesses and on strengthening research facilities.」
In addition to developing measurement methods and conducting clinical research for the depression biomarker, the company continues business development for related businesses and the strengthening of research facilities. - FY2019AdvancedAnnual report
「The company began selling the research-use exosome purification kit.」
The biomarker-related business advanced to the specific stage of launching sales of a research-use exosome purification kit. - FY2019-Q3AdvancedAnnual report
「In the biomarker business, we continued technology development and the establishment of a framework toward commercializing the biomarker for major depressive disorder (hereinafter, the “depression biomarker”), while also considering new pipelines and related businesses and establishing a sales structure for a research-use exosome purification kit.」
In addition to technology development and framework building for the depression biomarker, the company advanced the establishment of a sales structure for a research-use exosome purification kit as a related business. - FY2019-Q2RestatedAnnual report
「In the biomarker business, we continued technology development and organizational preparations aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
The company continues to develop the technology for the depression biomarker and establish the necessary framework, while considering new pipelines and related businesses. - FY2019-Q1RestatedAnnual report
「In the biomarker business, we continued technology development and organizational preparations aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
The company continues to develop the technology for the depression biomarker and establish the necessary framework. - FY2018-Q4RestatedAnnual report
「In this business segment, we worked on developing measurement methods using instrument-based and enzyme-based methods, as well as establishing a quality management system for clinical research, with a view to the practical application and commercialization of the depression biomarker.」
The company continues to develop measurement methods and establish a framework for clinical research toward the practical application and commercialization of the depression biomarker. - FY2018-Q2AdvancedAnnual report
「We also began a feasibility study and undertook other initiatives, including preparations for establishing a study group, toward clinical trials using depression biomarkers.」
The company described the start of a feasibility study and preparations to establish a study group as preparations for clinical research toward commercializing the depression biomarker. - FY2018-Q1RestatedAnnual report
「In the biomarker business, we advanced the development of research-use reagent kits and measuring instruments, as well as initiatives toward clinical research, with a view to commercializing the biomarker for major depressive disorder (hereinafter, the “depression biomarker”).」
The company continues to develop research-use reagent kits and measuring instruments and pursue clinical research with a view to commercializing the depression biomarker. - FY2017-Q4RestatedAnnual report
「In the biomarker business, we advanced the development of research-use reagent kits and measuring instruments, as well as initiatives toward clinical research, with a view to commercializing the biomarker for major depressive disorder (hereinafter, the “depression biomarker”).」
The company continues to develop research-use reagent kits and measuring instruments and pursue initiatives toward clinical research with a view to commercializing the depression biomarker. - FY2017First statedAnnual report
「The top priority in the biomarker business is the early practical application and commercialization of the depression biomarker, the pipeline with the highest expectations. Accordingly, we will concentrate management resources on developing products such as research-use reagents for this biomarker and on clinical development through the expansion of collaborating medical institutions, including university hospitals.」
The company identified the depression biomarker as its top-priority pipeline and, for the first time, stated as a separate issue its policy of concentrating management resources on product development, collaboration with medical institutions, and clinical development.